JPRN-UMIN000005910已完成1 期
Safety Evaluation of the Maintenance treatment of Sorafenib in Hepatocellular carcinoma patients with Tumor thrombus after palliative surgery - Sorafenib for TT
Tokyo University Hospital0 个研究点目标入组 12 人开始时间: 2011年7月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients treated with sorafenib or other molecular target drugs within 3 months before surgery; (2)Patients with a history of allergic reaction to sorafenib; (3)Pregnant and breastfeeding women or those who may possibly be pregnant; (4)Patients with serious complications (whether preoperative or postoperative); (5)Patients with distant metastasis; (6)Patients with other active malignancies (e.g., brain tumor); (7)Patients with underlying diseases other than viral hepatitis (e.g., autoimmune hepatitis, alcoholic hepatitis); (8)Patients with moderate or severe renal dysfunction (eGFR < 30 mL/min) including those on dialysis; (9)Patients with asthma; (10)Patients with uncontrolled hypertension or with thromboembolism, ischemic heart disease, unstable angina pectoris, heart failure, or cerebrovascular disorder that may affect the operability of the disease; (11)Patients with clinically relevant ascites (refractory ascites requiring therapeutic paracentesis); (12)Patients with previous liver transplantation; (13)Patients with esophageal varices that may cause bleeding (those who had gastrointestinal bleeding in the past month); (14)Patients with a current or past history of hepatic encephalopathy; (15)Patients under treatment with drugs affecting the activity of CYP3A4 or UGT1A9 (e.g., rifampicin) or drugs that may affect the serum concentration of sorafenib; (16)Patients orally taking crude drugs approved for the treatment of cancer (e.g., Sho-saiko-to); (17)Patients with diseases related to human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); or (18)Patients considered to be ineligible for participation in the study by the investigator or subinvestigator.
研究者
相似试验
已完成
3 期
Efficacy and safety of modify maintenance instillation Bacillus- calmette-guerin (BCG) in bladder cancerIRCT20220302054165N1Shahid Beheshti University of Medical Sciences64
已完成
不适用
Study of the efficacy and safety of maintenance Irinotecan in patients with extended small cell lung cancer after 4 courses of Cisplatin plus Irinotecan chemotherapy.JPRN-UMIN000008821Division of Thoracic Oncology, National Cancer Center Hospital East28
尚未招募
1 期
euroEPO – Type 2 Spinocerebellar Ataxia Phase I-IIType 2 Spinocerebellar AtaxiaRPCEC00000187Center of Molecular Immunology (CIM), CIMAB34
进行中（未招募）
不适用
Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögrens' syndromeMedDRA version: 8.1Level: PTClassification code 10023350Term: Keratoconjunctivitis siccakeratoconjunctivitis siccaEUCTR2006-003391-35-NLaboratoires THEA
招募中
不适用
The evaluation for safety and effectiveness of the laparoscopic radical hysterectomy and pelvic lymphadenectomy for stage IA, IB and IIA uterine cervical cancer.terine cervical cancerJPRN-UMIN000016183agoya University Graduate School of Medicine, Department of Obstetrics and Gynecology10